Appendix C

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
Antimicrobial Health Technology Evaluation
Cefiderocol for treating severe aerobic Gram-negative bacterial infections
Provisional stakeholder list of consultees and commentators

Consultees

Company/sponsor
- Shionogi (cefiderocol)

Patient/carer groups
- Bladder and Bowel UK
- Bladder Health UK
- British Lung Foundation
- Chronic Urinary Tract Infection Campaign
- GUTS UK
- Kidney Care UK
- Kidney Research UK
- National Kidney Federation
- Patients Association
- Specialised Healthcare Alliance

Professional groups
- Association for Respiratory Technology and Physiology
- Association of Anaesthetists
- Association of Clinical Biochemists - Microbiology Section
- Association of Renal Technologists
- Association of Respiratory Nurse Specialists
- Association of Surgeons of Great Britain and Ireland
- British Association for Immediate Care
- British Association for Parenteral & Enteral Nutrition
- British Association of Urological Nurses
- British Association of Urological Surgeons
Appendix C

- British Geriatrics Society
- British Infection Association
- British Medical Association
- British Renal Society
- British Society of Antimicrobial Chemotherapy
- British Society for Haematology
- British Society of Gastroenterology
- British Thoracic Society
- British Transplantation Society
- Faculty of Public Health
- Healthcare Infection Society
- Infection Prevention Society
- Intensive Care Society
- National Heart and Lung Institute
- NHS Blood and Transplant
- Royal College of Emergency Medicine
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Surgeons
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Surgical Dressing Manufacturers Association
- UK Clinical Pharmacy Association
- UK Critical Care Nursing Alliance
- UK Renal Pharmacy Group

Others
- Department of Health and Social Care
- NHS England and NHS Improvement

Provisional stakeholder list for the antimicrobial health technology evaluation of cefiderocol for treating severe aerobic Gram-negative bacterial infections
Issue date: December 2020
© NICE 2020. All rights reserved. Subject to Notice of rights.
• Northern Ireland Government
• Scottish Government
• Welsh Government
• NHS North Yorkshire CCG
• NHS Herefordshire and Worcestershire CCG

Commentators

General commentators
• All Wales Therapeutics and Toxicology Centre
• Allied Health Professionals Federation
• Board of Community Health Councils in Wales
• British National Formulary
• Care Quality Commission
• Department of Health, Social Services and Public Safety for Northern Ireland
• Healthcare Improvement Scotland
• Medicines and Healthcare Products Regulatory Agency
• National Association of Primary Care
• National Pharmacy Association
• NHS Alliance
• NHS Confederation
• Scottish Medicines Consortium
• Welsh Health Specialised Services Committee

Possible comparator companies
• Advanz Pharma (gentamicin)
• Aurobindo Pharma (piperacillin with tazobactam, meropenem)
• Beacon Pharma (colistimethate sodium)
• Bowmed Ibisqus (piperacillin with tazobactam, meropenem)
• Consilient Health (imipenem with cilastatin, ertapenem, meropenem)
• Flynn Pharma (tobramycin)
• Hospira UK (gentamicin, tobramycin)
Appendix C

- Kent Pharmaceuticals (fosfomycin)
- Menarini (meropenem with vaborbactam)
- Merck Sharpe & Dohme (ertapenem, imipenem with cilastatin and relebactam)
- Mylan (piperacillin with tazobactam, tigecycline)
- Panpharma UK (ertapenem)
- Pfizer (ceftazidime with avibactam, meropenem, tigecycline)
- Profile Pharma (colistimethate sodium)
- Ranbaxy UK (meropenem)
- Sandoz (piperacillin with tazobactam)
- Sanofi (gentamicin)
- Synchrony (meropenem)
- Teva UK (colistimethate sodium)
- Wockhardt UK (piperacillin with tazobactam, gentamicin)
- Zentiva (gentamicin)

**Relevant research groups**
- Cochrane Acute Respiratory Infections
- Cochrane Airways Group
- Cochrane Infectious Diseases Group
- Cochrane Kidney and Transplant Group
- Genomics England
- LifeArc
- MRC Clinical Trials Unit
- National Institute for Health Research
- UK Research and Innovation
- Wellcome Trust

**Associated Public Health groups**
- Advisory Committee on Antimicrobial Prescribing, Resistance and Healthcare Associated Infections (APRHAI)
- Public Health England
- Public Health Wales
NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

**Definitions**

**Consultees**
Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations and nominate clinical experts.

All non-company consultees are invited to submit a statement¹, respond to consultations and nominate clinical or patient experts.

**Commentators**
Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.